Sanofi's Jevtana still too expensive for NICE, despite end-of-life credentials rethink
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, maintains that Sanofi-Aventis’ docetaxel follow-on Jevtana (cabazitaxel) is too costly for treating prostate cancer patients on the National Health Service. Final negative draft guidance comes even though the institute changed its mind and recognised that the drug does in fact meet NICE's end-of-life criteria that gives it more scope to consider expensive drugs.